Who we are
What we do
Who we serve
Resources
Back
Who we are
What we do
Who we serve
Resources
About Us
Leadership
Infrastructure
Contact
Biologics
Cell Line Development
Protein Expression & Purification
Analytical Services
Process Development & Characterization
GMP Manufacturing Services
Antibody Discovery
Molecular Biology
Preclinical Efficacy Testing
Fibrosis
Oncology
Immunology and
In Vitro
Pharmacology
Infectious Diseases
Respiratory Diseases
Histology and Digital Pathology
Biotech
Biosimilars
Animal Health
Government and Academic Research
Webinar
Technical Content
Testimonials
News and Events
© 2025 Aragen Bioscience. All rights reserved
Close Search
Search
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Resources
News & Events
News
News
All
All
2024
2023
2024
Press Release
Aragen Bioscience Validates Getinge’s Single-Use Production Reactor (SUPR)
June 11, 2024
Know More
Press Release
Aragen's Validation Journey with Getinge's SUPR Single-Use Bioreactors
April 29, 2024
Know More
Press Release
Aragen operationalizes first phase of its Biologics manufacturing facility in India
March 27, 2024
Know More
2023
Press Release
Aragen setting up a $ 30 million bio-manufacturing site in India
October 30, 2023
Know More
Media Coverage
Analytical Prowess Powers Efficient CLD Through Data-Driven Decision-Making
October 17, 2023
Know More
Media Coverage
Forging robust partnerships in biologics development
September 16, 2023
Know More
Media Coverage
Aragen launches royalty-free CHO GS cell line development platform under RapTr2022
August 03, 2023
Know More
Media Coverage
Best practices & strategies for biotherapeutics production using a stable scale-up process
July 12, 2023
Know More
Media Coverage
Long-acting injectables for biologics: Current landscape and future perspective
June 11, 2023
Know More
Media Coverage
FAR Biotech and Aragen Life Sciences Enter into a Collaboration to Advance Preclinical Program in Neurodegeneration
May 26, 2023
Know More
Learn more about our end-
to-end capabilities
BACK TO TOP